Renovo Employee Directory
Biotechnology ResearchUnited Kingdom51-200 Employees
Renovo is a mid-sized biotechnology research company based in the United Kingdom. It concentrates on developing targeted oncology therapies and commercializing RenovoCath, an FDA-cleared drug-delivery device. The firm aims to improve cancer treatment by enabling localized delivery of chemotherapeutics to tumors, potentially increasing local potency while reducing systemic exposure. Its activities include platforms and approaches designed to support intra-arterial delivery of cancer drugs. The primary customers are oncology clinicians and healthcare organizations seeking more precise, localized cancer therapies. In 2026, the company announced that oxaliplatin received FDA orphan-drug designation for the treatment of pancreatic cancer, marking a regulatory milestone for its pipeline.